The Oswaldo Cruz Foundation (FIOCRUZ) Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials), is a multidisciplinary, integrated research consortium based in Rio de Janeiro, Brazil with two clinical research sites (CRS) located at the Institute de Pesquisa Clinica Evandro Chagas (IPEC CRS) and Hospital Geral de Nova Iguagu (HGNI CRS). Both sites offer routine clinical care for both """"""""at-risk"""""""" and HIV-infected persons and cater to the needs of certain disenfranchised populations, which include individuals who may be racial minorities, women, poverty stricken, uneducated, and/or substance abusers. As a whole, the FioTrials unit has unique strengths to offer the ACTG and HPTN networks, as an established and integrated unit leadership who is partnered with FIOCRUZ, a supportive research-driven institution, a participant population that complements the scientific agendas of both networks, and researchers with significant experience in the development of HIV/AIDS prevention and treatment strategies. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069476-05
Application #
8208878
Study Section
Special Emphasis Panel (ZAI1-BLG-A (M2))
Program Officer
Castillo, Blanca E
Project Start
2008-01-15
Project End
2012-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
5
Fiscal Year
2012
Total Cost
$2,088,387
Indirect Cost
$45,306
Name
Fundacao Oswaldo Cruz
Department
Type
DUNS #
899294177
City
Rio de Janeiro
State
Country
Brazil
Zip Code
21040--360
Adachi, Kristina; Xu, Jiahong; Yeganeh, Nava et al. (2018) Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission. PLoS One 13:e0189851
Fink, Valeria I; Jenkins, Cathy A; Castilho, Jessica L et al. (2018) Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America. Infect Agent Cancer 13:16
Palumbo, Philip J; Fogel, Jessica M; Hudelson, Sarah E et al. (2018) HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. J Acquir Immune Defic Syndr 77:484-491
Cespedes, Michelle S; Kang, Minhee; Kojic, Erna Milunka et al. (2018) Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1. Papillomavirus Res 6:15-21
Swindells, S; Gupta, A; Kim, S et al. (2018) Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003). Int J Tuberc Lung Dis 22:1016-1022
Castro, Rodolfo; Crathorne, Louise; Perazzo, Hugo et al. (2018) Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Med Res Methodol 18:53
Caro-Vega, Yanink; Belaunzarán-Zamudio, Pablo F; Crabtree-Ramírez, Brenda E et al. (2018) Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America. Open Forum Infect Dis 5:ofy004
Côrtes, Fernanda H; de Paula, Hury H S; Bello, Gonzalo et al. (2018) Plasmatic Levels of IL-18, IP-10, and Activated CD8+ T Cells Are Potential Biomarkers to Identify HIV-1 Elite Controllers With a True Functional Cure Profile. Front Immunol 9:1576
Luz, Paula M; Osher, Benjamin; Grinsztejn, Beatriz et al. (2018) The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. J Int AIDS Soc 21:e25096
Robertson, K; Oladeji, B; Jiang, H et al. (2018) HIV-1 and TB Co-infection in Multinational Resource Limited Settings: Increased neurological dysfunction. Clin Infect Dis :

Showing the most recent 10 out of 127 publications